<DOC>
	<DOCNO>NCT00514930</DOCNO>
	<brief_summary>The primary aim trial ass whether RFA aspirator device safe clinical benefit patient primary secondary malignant liver tumour</brief_summary>
	<brief_title>Multicentre Prospective Clinical Trial RFA Tumour Aspirator Treatment Primary Secondary Malignancies Liver</brief_title>
	<detailed_description>Patients unresectable primary secondary malignancy liver limit treatment option often give small survival benefit . RFA demonstrate effective local tumour eradication extend patient survival . In study RFA aspiration use treat unresectable primary secondary tumour liver . RFA use develop shell tissue destruction around tumour , aspiration remove tissue fluid centre lesion . The potential advantage aspirate ablation could reduce aerosol spread tumour within liver parenchyma peritoneum . Additionally , aspirate ablate tissue may reduce incidence systemic side effect relate RFA large lesion treat . This study would establish safety efficiacy RFA aspiration treatment unresectable primary/secondary malignancy liver . This protocol prospective multi-centre clinical trial use RFA aspiration treatment patient primary/secondary malignancy liver , suitable formal liver resection . The basis unresectability presence extra-hepatic disease , limited liver synthetic function , co-morbidity ( ASA &gt; 3 ) , bilobar disease anatomical location . Early late complication relate usage RFA aspirator analyse . Additionally , local recurrence long term survival assess . If use RFA aspirator produce improved survival minimal morbidity mortality . Then initial result justify depth study establish clinical role . II . SPECIFIC AIMS/OBJECTIVES The primary aim trial ass whether RFA aspirator device safe clinical benefit patient primary secondary malignant liver tumour . III . STUDY OVERVIEW It anticipate 100-200 participant recruit . The time period patient recruitment 2 year follow 3 year . The total study period 5 year order allow assessment complication , local ablation success survival benefit .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>Eligible participant 18 year old . Have unresectable primary/secondary malignant tumour liver . Unresectable criterion presence extrahepatic disease , limited liver synthetic function , comorbidity ( ASA 3 ) , bilobar disease anatomical location . Study specific sign informed consent also complete allow patient inclusion . Age young 18 year old Pregnant woman Uncorrectable coagulopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>radiofrequency ablation</keyword>
	<keyword>liver cancer</keyword>
	<keyword>complication</keyword>
	<keyword>liver tumor</keyword>
</DOC>